🇺🇸 FDA
Pipeline program

Cabozantinib Ipsen 60 mg film-coated tablets, XL092, XL092, XL092, BELZUTIFAN, Cabozantinib Ipsen 20 mg film-coated tablets, XL092

MK-6482-033

Phase 3 small_molecule active

Quick answer

Cabozantinib Ipsen 60 mg film-coated tablets, XL092, XL092, XL092, BELZUTIFAN, Cabozantinib Ipsen 20 mg film-coated tablets, XL092 for Renal Cell Carcinoma is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Renal Cell Carcinoma
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials